Indicative listing context
Abridge Stock Price (Pre-IPO)
Ask for the Abridge stock price and the honest answer is that none exists officially, since the healthcare AI company remains private and unlisted. In place of a market quote, Segmara maintains an indicative pre-IPO reference mark for Abridge, shown above with the date it was set, compiled from private-market signals across healthcare AI. Abridge is offered through a direct structure, and a free email tracker lets you follow the mark before any listing happens. The catalogue also lines Abridge up against other healthcare AI companies for comparison.
Get free Abridge trackerThis page is not an offer, allocation, recommendation, investment application, payment workflow, brokerage instruction, or issuer-affiliated workflow.
Limited intake
Start with name and email only.
Use the inquiry form to open one account portfolio. No public ID upload, payment card, bank detail, wallet address, or document upload is requested on this step.
Request review with name + email1Submit limited interest
2Route fit is checked
3Private follow-up only if appropriate
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | Private | Not reliably public | Do not invent a seed price when the source set is thin. |
| Growth rounds | Private | Company and market sources vary | Use public sources, official releases, and private follow-up. |
| Segmara listing | Current | $180.00/sh · as of July 5, 2026 | Indicative context for starting the review process. |
| IPO status | Current | No public ticker shown here | Visitors start with private-market review on Segmara. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
Regulation D filings on record
The SEC full-text index lists 2 Form D filings for Abridge AI Inc. (CIK 1737537), the filer behind Abridge. The most recent was filed 2025-06-30 and reports $315,934,583 sold of a $318,998,519 offering.
| Filed | Amount sold | Offering size | First sale | Source |
|---|---|---|---|---|
| 2025-06-30 | $315,934,583 | $318,998,519 | 2025-06-12 | SEC filing |
| 2024-03-08 | $141,103,188 | $149,999,730 | 2024-02-22 | SEC filing |
A Form D reports an exempt offering under Regulation D: what the issuer told the SEC it raised, not a valuation and not a per-share price.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /abridge-stock-price | Stable URL path for AI and search extraction. |
| Article title | Abridge Stock Price (Pre-IPO) | Main page topic. |
| Attached public sources | 4 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 50 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Request-quote listings | 13 | Catalogue listings where a public price is intentionally not invented. |
| Company | Abridge | Named company covered by this buying guide. |
| Symbol label | ABRG | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Healthcare AI | Catalogue sector used for comparison and internal linking. |
| Listing structure | Direct | How the listing is categorized on Segmara. |
| Segmara mark | $180.00/sh · as of July 5, 2026 | Visible listing mark or request-quote state. |
| Sector peer count | 1 | Number of live Segmara listings in Healthcare AI. |
| Structure peer count | 12 | Number of live Segmara listings categorized as Direct. |
| Price rank | 12 of 37 | Ranked highest-to-lowest among Segmara listings with visible marks. |
| Price percentile | 70th | Percentile among visible Segmara catalogue marks. |
| Catalogue median mark | $82.00 | Median visible mark across priced Segmara listings. |
| Premium/discount to median | +120% | Difference between this listing mark and the catalogue median mark. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Formation | Private | Early ownership | The first value creation happens before ordinary public-market access. |
| Growth rounds | Private | Institutional repricing | Later rounds and tenders create the price history buyers study. |
| Segmara listing | Current | $180.00/sh · as of July 5, 2026 | Retail buyers can start from the public Segmara listing. |
| Exit path | Future | IPO, tender, acquisition, or continued private status | Liquidity timing remains company-specific. |
| Chart metric | Score | Interpretation |
|---|---|---|
| Listing price percentile | 70 / 100 | $180.00/sh · as of July 5, 2026 ranks 12 of 37 priced listings |
| Source depth | 68 / 100 | 4 source links |
| Sector peer signal | 42 / 100 | 1 Healthcare AI listing(s) |
| Structure specificity | 88 / 100 | Direct |
Analytical lens
Search intent
The search behind 'Abridge Stock Price (Pre-IPO)' is an access-intent query. People want to know where they can start interest in Abridge private-market exposure without needing a private equity relationship, fund connection, or insider network.
Access path
segmara.com turns that search into a simple path: browse the listing, create an account, choose the company, and start the private-share inquiry. Final pricing and availability still depend on the route, but the starting point is public and straightforward.
Segmara role
Segmara works as a private-market access layer for interested visitors. The site helps visitors discover healthcare ai categories that were previously hard to research and moves them into an account-based inquiry in a few steps.
Private-share path map
From gatekept to accessible
BrowseRetail investor finds a private-company listing.
AccountBuyer creates one Segmara account.
RequestBuyer starts the private-share purchase request.
CloseAvailability, price, approvals, and final terms are handled privately.
Access-friction chart
Illustrative map of where the old private-market process was hardest and where Segmara makes the starting point easier.
Old-market frictionPrivate networks and institutional access
Segmara discoveryPublic listings retail buyers can browse
Account workflowOne account to start the purchase request
Private closeFinal terms handled after buyer interest
How access works
- Live indicative mark for Abridge renders in the data summary below.
- Compare Abridge with other healthcare AI names in the catalogue.
- Track the indicative price free by email. No card, no documents, no brokerage account.
Risk notes
- Private-company exposure can be illiquid, transfer-restricted, and hard to value.
- Indicative marks and reported valuations are orientation points, not executable quotes.
- Availability of any route can depend on jurisdiction, eligibility, structure, and approval.
What private follow-up needs
- Which name or category do you want reviewed?
- Are you an individual, advisor, family office, institution, or other profile?
- What jurisdiction or country should the review consider?
- Do you already know your accredited investor or qualified purchaser status?
- What time horizon and liquidity constraints matter for you?
- Are you asking about private-company exposure, event-market exposure, or both?
Public source links
Related reviews
Questions
Can I start private-share interest for Abridge through this page?
Yes. This page can collect limited interest for Abridge, but it does not create an offer, allocation, subscription, payment instruction, or issuer-affiliated workflow. Final availability, eligibility, documents, and terms remain route-specific.
What is the first step?
Submit a limited share inquiry with the relevant interest, contact details, jurisdiction context, and consent. Any later account, document, or payment step is handled separately in private follow-up.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Abridge or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
What is Abridge's stock price today?
Abridge is private, so there is no official public stock price. Segmara publishes an indicative pre-IPO reference mark in the data summary on this page. It is not a live exchange quote and not an offer to sell.
Is Abridge publicly traded?
No. Abridge has not held an IPO and its shares do not trade on any public exchange. Any price shown for Abridge is an indicative private-market estimate.
How can I get exposure to Abridge?
Segmara is review-first. You can create an account portfolio, fund portfolio credits, and follow Abridge listings as they appear. Availability, eligibility, and final terms stay review-controlled, and nothing is guaranteed.
What is Abridge worth?
Segmara does not state a fixed valuation for Abridge. The indicative mark in the data summary below reflects private-market signals, and reported valuations elsewhere are orientation points, not executable quotes.
Next step
Track Abridge free.
Get the indicative Abridge price by email. Free, email only. No card, no documents, no brokerage account, and no allocation promise.
Get the free Abridge tracker